Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# **Appendix 3B**

## New issue announcement, application for quotation of additional securities and agreement

given to

	ation or documents not available now must be given Ecome ASX's property and may be made public.	en to ASX as soon as available. Information and documents
Introduce	ed 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01.	/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12
	of entity	
ALG	AE.TEC LIMITED	
ABN		
16 12	4 544 190	
We (t	he entity) give ASX the following informa	tion.
	1 - All issues ust complete the relevant sections (attach sheets if the	ere is not enough space).
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Ordinary fully paid shares     Listed options
2	Number of <sup>+</sup> securities issued or to be issued (if known) or maximum number which may be issued	<ol> <li>Up to 266,403,087 ordinary fully paid shares</li> <li>Up to 133,201,543 listed options</li> </ol>
3	Principal terms of the <sup>+</sup> securities (eg, if options, exercise price and expiry date; if partly paid <sup>+</sup> securities, the amount outstanding and due dates for payment; if <sup>+</sup> convertible securities, the conversion price and dates for conversion)	<ol> <li>Ordinary fully paid shares</li> <li>Listed options with an exercise price of \$0.05 and an expiry date of 28 July 2020</li> </ol>

<sup>+</sup> See chapter 19 for defined terms.

#### New issue announcement

Do the \*securities rank equally in all respects from the date of allotment with an existing \*class of quoted \*securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

- 1. Ordinary fully paid shares rank equally with existing ordinary shares.
- 2. New class of Listed options will rank equally with ordinary shares upon exercise.

5 Issue price or consideration

1. Ordinary shares: \$0.03

2. Listed options: \$0.05

- 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)
- Fund the research and development of new products from medicinal marijuana and algae as announced through our collaboration agreement with WinterGarden Biosciences
- Further develop Algae.Tec's lighting technology for specific use in the medicinal marijuana industry
- For the expansion and improvement of the existing algae growth facilities in Cumming Georgia
- To expand the biomass supply chains and employ specific personnel for the medicinal marijuana industry
- To repay debt and for general working capital
- 6a Is the entity an <sup>+</sup>eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h *in relation to the* +*securities the subject of this Appendix 3B*, and comply with section 6i

No

6b The date the security holder resolution under rule 7.1A was passed

N/A

6c Number of \*securities issued without security holder approval under rule 7.1

Nil

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of securities issued under an exception in rule 7.2	1. Up to 266,403,08 shares 2. Up to 133,201,543 l	7 ordinary fully paid isted options
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Remaining 7.1 capa Remaining 7.1A capacit	acity – 19,941,410 y – 35,386,611
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	29 July 2017	
		Number	+Class
8	Number and +class of all +securities quoted	621,607,203	Ordinary Shares
	on ASX ( <i>including</i> the securities in section 2 if applicable)	133,201,543	Listed options expiring 28 July 2020 with an exercise price of \$0.05
		Number	+Class
	Number and +class of all +securities not	1,6111001	J1400
	quoted on ASX ( <i>including</i> the securities in section 2 if applicable)	28,728,607	Unlisted options exercisable at \$0.1636 on or before 20 January 2019
		1	Convertible Note maturing on 9 July 2016 with a conversion price at \$0.075 and subject to adjustments in accordance with the terms and

<sup>+</sup> See chapter 19 for defined terms.

I	conditions of the
	Convertible Notes.
1,000,000	Unlisted options exercisable at \$0.20 on or before 1 March 2018
16,000,000	Unlisted options exercisable at \$0.09 on or before 30 June 2019
650,000	Convertible Notes maturing on of 22 July 2017 with a conversion price of \$0.049 and otherwise in accordance with the terms and conditions of the Convertible Notes
125,000	Convertible Notes maturing on 8 August 2017 with a Conversion price of \$0.049 and otherwise in accordance with the terms and conditions of the Convertible Notes.
90,000	Convertible Notes maturing on 6 October 2017 with a conversion price of \$0.049 and otherwise in accordance with the terms and conditions of the Convertible Notes.
1	Convertible Note A 'Maturity Date' of 7 January 2018 with a conversion price of \$0.10
0	Convertible Notes Maturing on 8 July 2017 with an outstanding aggregate face value of US\$0.00 a conversion price of lower of;  15% discount from the average of the lowest 5 daily
	VWAPS in the 10 trading days prior to conversion or Fixed price of \$0.075 AUD
1	Convertible Note  A Maturiety date of 18 months from date of issue  Conversion price of \$0.10
	• Interest reate of 10%

<sup>+</sup> See chapter 19 for defined terms.

	per annum – interest payable in cash  In the event of conversion, noteholder will be granted one option for every one Share issued at an exercise price of \$0.075 and 25 January 2018
1	Convertible Note:  • Face vaule of US\$166,667  • A maturity date of 36 months from date of issue  • Interest rate of 10% per annum  • The note can be converted into shares at a conversion price that is the lower of  • \$0.05 per share  • A 10% discount to the 5 day VWAP prior to the date of conversion
1	Convertible Note:  Face value of US\$166,666  A maturity date of 36 months from date of issue  Interest rate of 10% per annum  The note can be converted into shares at a conversion price that is the lower of  \$0.05 per share  A 10% discount to the 5 day VWAP prior to the date of conversion
1	Convertible Note:  Face value of US\$166,667  A maturity date of 36 months from date of issue  Interest rate of 10% per annum  The note can be converted into shares at a conversion price that is the lower of  \$0.05 per share  A 10% discount to the 5 day

<sup>+</sup> See chapter 19 for defined terms.

VWAP prior to the date conversion Convertible Notes Maturing on 6 May 2018 with a conversion price of lower of; 250,000 15% discount from the average of the lowest 5 daily VWAPS in the 10 trading days prior to conversion or Fixed price of \$0.075 AUD Convertible Notes Maturing on 27 June 2018 with a conversion price of lower of; 75,000 15% discount from the average of the lowest 5 daily VWAPS in the 10 trading days prior to conversion or Fixed price of \$0.075 AUD A maturity date of 23 September 2017 Interest rate of 2% compounded per 1 month plus 7% of the total outstanding at maturity date. Note is convertible at an issue price of \$0.03. Dividend policy (in the case of a trust, No dividend policy established distribution policy) on the increased capital Part 2 - Bonus issue or pro rata issue N/A No renounceable or non-Renounceable

Is the issue renounceable?

Is security holder approval required?

(interests)

10

11

12

<sup>+</sup> See chapter 19 for defined terms.

13	Ratio in which the *securities will be offered	<ol> <li>3 ordinary shares for every 4 shares held</li> <li>1 free attaching options for every 2 shares issued</li> </ol>
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	<ol> <li>Ordinary fully paid shares</li> <li>Listed options</li> </ol>
15	<sup>+</sup> Record date to determine entitlements	7 July 2017
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	No
17	Policy for deciding entitlements in relation to fractions	Round down to nearest whole number
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	All countries other than Australia and New Zealand
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	21 July 2017
20	Names of any underwriters	N/A
21	Amount of any underwriting fee o commission	r N/A
22	Names of any brokers to the issue	CPS Capital Group Pty Ltd
23	Fee or commission payable to the broker to the issue	<ul> <li>7.5 million options on the same terms as offered to shareholders.</li> <li>\$65,000. CPS will take this fee in scrip under the offer</li> <li>1% of the total amount raised. CPS will take this fee in scrip under the offer.</li> <li>5% on any shortfall placed by CPS. All selling fees will be paid by CPS.</li> </ul>
24	Amount of any handling fee payable to brokers who lodge acceptances o renunciations on behalf of +security holders	
25	If the issue is contingent on *security holders' approval, the date of the meeting	y N/A

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B

#### New issue announcement

	26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	To be lodged with ASX on 4 July 2017 and sent to shareholders 12 July 2017	
	27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	5 July 2017	
	28	Date rights trading will begin (if applicable)	6 July 2017	
	29	Date rights trading will end (if applicable)	14 July 2017	
	30	How do +security holders sell their entitlements in full through a broker?	Contact your stockbroker amd refer to details provided in the Prospectus and the accompanying Entitlement and Acceptance Form	
	31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	Contact your stockbroker amd refer to details provided in the Prospectus and the accompanying Entitlement and Acceptance Form	
	32	How do *security holders dispose of their entitlements (except by sale through a broker)?	Contact the Company's Share Registry – Computershare Investor Services refer to details provided in the Prospectus and the accompanying Entitlement and Acceptance	
	33	<sup>+</sup> Despatch date	12 July 2017	
Part 3 - Quotation of securities  You need only complete this section if you are applying for quotation of securities				
34	Type of securities (tick one)			
(a)		Securities described in Part 1		
(b)		All other securities  Example: restricted securities at the end of the escrowed per incentive share securities when restriction ends, securities issue		

### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

+ See chapter 19 for defined terms.

	to indicate ments	you are providing the information or
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37		A copy of any trust deed for the additional *securities

<sup>+</sup> See chapter 19 for defined terms.

#### Entities that have ticked box 34(b) 38 Number of securities for which <sup>+</sup>quotation is sought 39 Class of \*securities for which quotation is sought 40 Do the \*securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security) +Class Number 42 Number and +class of all +securities quoted on ASX (including the securities in clause 38)

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the <sup>+</sup>securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 3 July 2017

(Director/Company secretary)

Print name: Peter Hatfull

== == == == ==

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for \*eligible entities

Introduced 01/08/12

#### N/A

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	339,879,095	
<ul><li>Add the following:</li><li>Number of fully paid ordinary securities</li></ul>	609,592 Shares (28/07/2016)	
<ul><li>issued in that 12 month period under an exception in rule 7.2</li><li>Number of fully paid ordinary securities</li></ul>	551,658 Shares (28/07/2016) 893,274 Shares (09/09/2016)	
<ul> <li>issued in that 12 month period with shareholder approval</li> <li>Number of partly paid ordinary securities that became fully paid in that 12 month period</li> </ul>	774,018 Shares (26/10/16) 471,938 Shares (26/10/16) 765,127 Shares (21/11/16)	
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	1,106,730 Shares (01/12/16) 1,230,436 Shares (23/12/16) 1,283,578 Shares (25/01/17) 471,938 Shares (31/01/17) 1,304,688 Shares (20/2/17) 2,032,867 Shares (6/4/17)	
	392,219 Shares (10/5/17) 2,098,958 Shares (03/07/17) 266,403,087 Shares (subject to this Appendix 3B	
	Total: 620,269,203	
Subtract the number of fully paid ordinary securities cancelled during that 12 month period		
"A"	620,269,203	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15 [Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	93,040,380
Step 3: Calculate "C", the amount of pl that has already been used	acement capacity under rule 7.1
<b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	12,344,503 Shares (350,000 Convertible Notes)
<ul> <li>Under an exception in rule 7.2</li> </ul>	1,338,000 Shares
<ul><li>Under rule 7.1A</li><li>With security holder approval under rule 7.1</li></ul>	9,017,047 Shares (250,000 Convertible Notes)
or rule 7.4	2,877,624 Shares (75,000 Convertible Notes)
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	7,561,333 Shares (1 Convertible Note)
	33,138,50
"C"	33,138,507
Step 4: Subtract "C" from ["A" x "B"] to capacity under rule 7.1	o calculate remaining placement
"A" x 0.15 Note: number must be same as shown in Step 2	93,040,386
Subtract "C"  Note: number must be same as shown in Step 3	33,138,507
<i>Total</i> ["A" x 0.15] – "C"	59,901,873
	<u> </u>

<sup>+</sup> See chapter 19 for defined terms.

## Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	620,269,203	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	62,026,920	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	0	
Notes:		
This applies to equity securities – not just ordinary securities		
Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed		
Do not include equity securities issued under rule 7.1 (they must be dealt with		
in Part 1), or for which specific security holder approval has been obtained		
It may be useful to set out issues of securities on different dates as separate line items		
"E"	0	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	62,026,920	
Note: number must be same as shown in Step 2		
Subtract "E"	0	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	62,026,920	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.